BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BioCryst Pharmaceuticals (Nasdaq: BCRX) has granted equity-based compensation to nine newly-hired employees as employment inducements. The compensation package includes:
- Stock options to purchase 36,700 shares at $8.29 per share (equal to closing price on grant date)
- Restricted stock units (RSUs) covering 71,400 shares of common stock
Both options and RSUs were granted on September 2, 2025, and will vest in four equal annual installments. The options have a 10-year term and were granted under BioCryst's Inducement Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha assegnato compensi azionari a nove nuovi dipendenti come incentivo all'assunzione. Il pacchetto prevede:
- Opzioni su azioni per acquistare 36.700 azioni a $8,29 per azione (pari al prezzo di chiusura del giorno di concessione)
- Unità di azioni vincolate (RSU) per 71.400 azioni di capitale sociale
Opzioni e RSU sono state concesse il 2 settembre 2025 e maturano in quattro rate annuali uguali. Le opzioni hanno una durata di 10 anni e sono state concesse ai sensi del Piano di Incentivazione Azionaria per Inducement di BioCryst, in conformità con la Regola di quotazione Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) ha otorgado compensación basada en acciones a nueve empleados recién contratados como incentivo por contratación. El paquete incluye:
- Opciones sobre acciones para comprar 36.700 acciones a $8,29 por acción (equivalente al precio de cierre en la fecha de concesión)
- Unidades de acciones restringidas (RSU) que cubren 71.400 acciones ordinarias
Tanto las opciones como las RSU se otorgaron el 2 de septiembre de 2025 y se consolidarán en cuatro cuotas anuales iguales. Las opciones tienen un plazo de 10 años y se otorgaron bajo el Plan de Incentivos de Capital por Inducción de BioCryst, de conformidad con la Norma de Cotización Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX)는 채용 유인을 위해 신입 직원 9명에게 주식 기반 보상을 부여했습니다. 보상 패키지는 다음과 같습니다:
- 주당 $8.29에 36,700주를 매수할 수 있는 스톡옵션 (부여일 종가와 동일)
- 보통주 71,400주에 해당하는 제한부주식단위(RSU)
옵션과 RSU는 2025년 9월 2일에 부여되었으며, 4년간 연간 동일 분할로 베스팅됩니다. 옵션의 유효기간은 10년이며, Nasdaq 상장 규칙 5635(c)(4)에 따라 BioCryst의 인듀스먼트 주식 인센티브 플랜에 따라 부여되었습니다.
BioCryst Pharmaceuticals (Nasdaq: BCRX) a accordé des rémunérations en actions à neuf nouveaux employés à titre d'incitation à l'embauche. Le dispositif comprend :
- Des options d'achat de 36 700 actions au prix de 8,29 $ par action (équivalent au cours de clôture à la date d'attribution)
- Des unités d'actions restreintes (RSU) représentant 71 400 actions ordinaires
Les options et les RSU ont été attribuées le 2 septembre 2025 et acquerront des droits par quatre versements annuels égaux. Les options ont une durée de 10 ans et ont été octroyées dans le cadre du Inducement Equity Incentive Plan de BioCryst, conformément à la règle de cotation Nasdaq 5635(c)(4).
BioCryst Pharmaceuticals (Nasdaq: BCRX) hat neun neu eingestellten Mitarbeitern aktienbasierte Vergütungen als Einstellungsanreize gewährt. Das Paket umfasst:
- Aktienoptionen zum Kauf von 36.700 Aktien zu $8,29 pro Aktie (entsprechend dem Schlusskurs am Gewährungstag)
- Restricted Stock Units (RSUs) für 71.400 Aktien des Stammkapitals
Sowohl die Optionen als auch die RSUs wurden am 2. September 2025 gewährt und vesten in vier gleichen jährlichen Raten. Die Optionen haben eine Laufzeit von 10 Jahren und wurden im Rahmen des Inducement Equity Incentive Plan von BioCryst gemäß der Nasdaq Listing Rule 5635(c)(4) gewährt.
- None.
- None.
RESEARCH TRIANGLE PARK, N.C., Sept. 03, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 36,700 shares, and restricted stock units (RSUs) covering an aggregate of 71,400 shares, of BioCryst common stock. The options and RSUs were granted as of September 2, 2025, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
The options have an exercise price of
About BioCryst Pharmaceuticals
BioCryst Pharmaceuticals is a global biotechnology company with a deep commitment to improving the lives of people living with hereditary angioedema and other rare diseases. BioCryst leverages its expertise in structure-guided drug design to develop first-in-class or best-in-class oral small-molecule and protein therapeutics to target difficult-to-treat diseases. BioCryst has commercialized ORLADEYO® (berotralstat), the first oral, once-daily plasma kallikrein inhibitor, and is advancing a pipeline of small-molecule and protein therapies. For more information, please visit www.biocryst.com or follow us on LinkedIn.
BCRXW
Contact:
Investors:
investorrelations@biocryst.com
Media:
media@biocryst.com
FAQ
What equity compensation did BioCryst (BCRX) grant to new employees in September 2025?
What is the vesting schedule for BioCryst's (BCRX) September 2025 inducement grants?
What is the exercise price of BioCryst's (BCRX) September 2025 inducement stock options?
How long is the term for BioCryst's (BCRX) September 2025 inducement stock options?
